HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels
- 1 October 2014
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 61 (4) , 730-737
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis BGastroenterology, 2012
- Role of carnitine in diseaseNutrition & Metabolism, 2010
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid ConcentrationsPLOS Genetics, 2009
- A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in AsiansNature Genetics, 2009
- L-carnitine, a diet component and organic cation transporter OCTN ligand, displays immunosuppressive properties and abrogates intestinal inflammationClinical and Experimental Immunology, 2009
- Principal components analysis corrects for stratification in genome-wide association studiesNature Genetics, 2006
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Anti‐Human Immunodeficiency Virus (HIV) Activity, Safety, and Pharmacokinetics of Adefovir Dipivoxil (9‐[2‐(bis‐pivaloyloxymethyl)‐phosphonylmethoxyethyl]adenine) in HIV‐Infected PatientsThe Journal of Infectious Diseases, 1997
- Plasma carnitine and body compositionClinica Chimica Acta, 1976